Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.
Xiaolin Zhang, PhD
Advertisement
Xiaolin Zhang, PhD, is the chief executive officer of Dizal Pharmaceuticals.
Articles by Xiaolin Zhang, PhD
Advertisement
Latest Updated Articles
Sunvozertinib Shows Promise in Treating Pretreated EGFR+ Lung CancerPublished: July 9th 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
